Introduction
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1)
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Abbisko Therapeutics Co Ltd, H2 2020
Pipeline by Akero Therapeutics Inc, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by Betta Pharmaceuticals Co Ltd, H2 2020
Dormant Products, H2 2020
Discontinued Products, H2 2020

List of Figures
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned
• Abbisko Therapeutics Co Ltd
• Akero Therapeutics Inc
• Bayer AG
• Betta Pharmaceuticals Co Ltd
• BioArdis LLC
• Blueprint Medicines Corp
• Eddingpharm Inc
• Eisai Co Ltd
• Eli Lilly and Co
• EUSOL Biotech Co Ltd
• Everest Medicines Ltd
• Genosco Inc
• H3 Biomedicine Inc
• ImmunoForge Co Ltd
• Incyte Corp
• InnoCare Pharma Ltd
• Johnson & Johnson
• Merck & Co Inc
• NGM Biopharmaceuticals Inc
• QED Therapeutics Inc
• Vichem Chemie Research Ltd